STOCK TITAN

Xilio Therapeutics: Logos reports 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Xilio Therapeutics, Inc. (XLO) is named in a beneficial-ownership disclosure by six reporting persons: Logos Global Management LP, Logos Global Management GP LLC, Logos Opportunities Fund IV LP, Logos Opportunities IV GP LLC, William Arsani and Graham Walmsley. Each reports shared voting and dispositive power over 730,315 shares, representing 9.99% of the class.

The reported securities consist of pre-funded warrants to acquire 476,250 common shares and Series A Warrants to acquire 476,250 common shares; both are subject to a 9.99% beneficial ownership limitation. The percentage calculation uses 6,580,153 common shares outstanding as of August 10, 2026.

Reported beneficial ownership 730,315 shares Each of the six reporting persons; shared voting and dispositive power.
Reported ownership percentage 9.99% Calculated using 6,580,153 common shares outstanding as of August 10, 2026.
Pre-funded warrants 476,250 shares Common shares the warrants can acquire; subject to a 9.99% beneficial ownership limitation.
Series A Warrants 476,250 shares Common shares the warrants can acquire; subject to a 9.99% beneficial ownership limitation.
Common shares outstanding 6,580,153 shares As of August 10, 2026; used for the ownership percentage calculation.
pre-funded warrants technical
"pre-funded warrants to acquire 476,250 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series A Warrants technical
"Series A Warrants to acquire 476,250 shares"
Series A warrants are financial tools that give the holder the right to buy shares of a company at a specific price within a certain period. They are often issued alongside investments to provide additional potential profit if the company's value increases. For investors, they can offer a chance to benefit from future growth without committing immediate capital to buying shares.
beneficial ownership limitation regulatory
"subject to a 9.99% beneficial ownership limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
shared dispositive power regulatory
"Shared Dispositive Power 730,315.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much XLO stock do the reporting persons report owning?

Each of the six reporting persons lists 730,315 shares as the beneficial-ownership amount, equal to 9.99% of XLO's common-stock class. The described securities are pre-funded warrants and Series A Warrants, each covering 476,250 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





98422T209

(CUSIP Number)
06/05/2025

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported herein consist of pre-funded warrants to acquire 476,250 shares of Common Stock and Series A Warrants to acquire 476,250 shares of Common Stock, which warrants are subject to a 9.99% beneficial ownership limitation. Percentage calculated based on 6,580,153 shares of Common Stock outstanding on August 10, 2026, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2026.


SCHEDULE 13G



Logos Global Management LP
Signature:/s/ Arsani William
Name/Title:Managing Partner
Date:11/16/2026
Logos Global Management GP LLC
Signature:/s/ Arsani William
Name/Title:Managing Member
Date:11/16/2026
Logos Opportunities Fund IV LP
Signature:/s/ Arsani William
Name/Title:Managing Member
Date:11/16/2026
Logos Opportunities IV GP LLC
Signature:/s/ Arsani William
Name/Title:Managing Member
Date:11/16/2026
Arsani William
Signature:/s/ Arsani William
Name/Title:Reporting person
Date:11/16/2026
Graham Walmsley
Signature:/s/ Graham Walmsley
Name/Title:Reporting person
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G

Keep reading